NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy

被引:3
|
作者
Benedetti, Luana [1 ]
Facco, Monica [2 ]
Franciotta, Diego [3 ]
Dalla Torre, Chiara [4 ]
Campagnolo, Marta [4 ]
Lucchetta, Marta [4 ]
Boscaro, Elisa [2 ]
Ermani, Mario [4 ]
Del Sette, Massimo [1 ]
Berno, Tamara [2 ]
Candiotto, Laura [2 ]
Zambello, Renato [2 ]
Briani, Chiara [4 ]
机构
[1] Osp S Andrea, Dept Neurol, La Spezia, Italy
[2] Univ Padua, Dept Med DIMED, I-35100 Padua, Italy
[3] Natl Inst Neurol C Mondino, IRCCS, Lab Neuroimmunol, Pavia, Italy
[4] Univ Padua, Dept Neurosci, I-35100 Padua, Italy
关键词
Natural killer (NK) cells; CD94/NKG2A; Myelin associated glycoprotein; Anti-MAG antibodies; IgM; Monoclonal gammopathy; Rituximab; NATURAL-KILLER-CELLS; PERIPHERAL-BLOOD; MULTIPLE-SCLEROSIS; MONOCLONAL-ANTIBODY; T-CELLS; AUTOIMMUNE; NEUROPATHY; DISEASE;
D O I
10.1016/j.jns.2013.05.015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Natural killer (NK) cells can bridge innate and acquired immunity, and play a role in autoimmunity. A few studies evaluated the distribution of NK cells and the expression of their receptors in chronic immune-mediated demyelinating polyneuropathies. We investigated NK cell distribution and NK cell receptor expression in 20 naive patients with anti-MAG polyneuropathy (MAG-PN). Methods: Using flow cytometry, we analysed NK cells and a series of NK cell receptors in the peripheral blood of patients with MAG-PN, and, as controls, in patients with chronic inflammatory demyelinating peripheral polyradiculoneuropathy (CIDP) and in healthy subjects. Six MAG-PN patients were also tested after rituximab treatment. Results: At baseline the percentage of NK cells did not differ among the groups. KIR2DL2 receptor expression in MAG-PN patients was higher, andCD94/NKG2A receptor expression in both MAG-PN and CIDP patients was lower than in healthy controls. These abnormalities did not correlate with any clinical or demographic variable. No modification was found after rituximab therapy. Conclusions: The data suggest that MAG-PN shows abnormalities in NK cell receptors that characterise other autoimmune diseases, and cannot help in differential diagnosis with CIDP. The impairment of the relevant CD94/NKG2A inhibitory pathway, which might play a central role in the development and perpetuation of MAG-PN, warrants further functional investigations. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:86 / 89
页数:4
相关论文
共 50 条
  • [1] NK CELLS AND NK CELL RECEPTORS IN PATIENTS WITH ANTI-MAG NEUROPATHY TREATED WITH RITUXIMAB
    Benedetti, L.
    Facco, M.
    Campagnolo, M.
    Dalla, Torre C.
    Lucchetta, M.
    Berno, T.
    Candiotto, L.
    Schenone, A.
    Mancardi, G. L.
    Zambello, R.
    Briani, C.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2011, 16 : S2 - S2
  • [2] B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy
    Benedetti, Luana
    Zardini, Elisabetta
    Briani, Chiara
    Beronio, Alessandro
    Gastaldi, Stefania
    Jarius, Sven
    Mancardi, Gian Luigi
    Schenone, Angelo
    Franciotta, Diego
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2011, 82 (11): : 1291 - 1294
  • [3] Rituximab in anti-MAG polyneuropathy
    Benedetti, L
    Gobbi, M
    Ghiglione, E
    Vigo, T
    Carpo, M
    Cocito, D
    Briani, C
    Caporale, CM
    Abbruzzese, M
    Mancardi, G
    Schenone, A
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2005, 10 : 5 - 5
  • [4] Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies
    Emilien Delmont
    P. Y. Jeandel
    C. Benaïm
    E. Rosenthal
    J. G. Fuzibet
    C. Desnuelle
    Journal of Neurology, 2011, 258 : 1717 - 1719
  • [5] Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies
    Delmont, Emilien
    Jeandel, P. Y.
    Benaim, C.
    Rosenthal, E.
    Fuzibet, J. G.
    Desnuelle, C.
    JOURNAL OF NEUROLOGY, 2011, 258 (09) : 1717 - 1719
  • [6] SKEWED EXPRESSION OF NATURAL KILLER (NK) CELL RECEPTORS IN PATIENTS WITH ANTI-MAG POLYNEUROPATHY
    Briani, C.
    Benedetti, L.
    Facco, M.
    Dalla Torre, C.
    Campagnolo, M.
    Lucchetta, M.
    Berno, T.
    Candiotto, L.
    Schenone, A.
    Mancardi, G. L.
    Zambello, R.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2011, 16 : S12 - S13
  • [7] Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy
    Zara, Gabriella
    Zambello, Renato
    Ermani, M.
    CLINICAL NEUROPHYSIOLOGY, 2011, 122 (12) : 2518 - 2522
  • [8] Improvement of quality of life in anti-MAG polyneuropathy patients responder to rituximab
    Benedetti, L.
    Padua, L.
    Briani, C.
    Fiorina, E.
    Mancardi, G. L.
    Nobile-Orazio, E.
    Schenone, A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2008, 13 (02) : 160 - 161
  • [9] Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies
    Renaud, S
    Gregor, M
    Fuhr, P
    Lorenz, D
    Deuschl, G
    Gratwohl, A
    Steck, AJ
    MUSCLE & NERVE, 2003, 27 (05) : 611 - 615
  • [10] Long-term efficacy of Rituximab in anti-mag polyneuropathy
    Benedetti, L.
    Briani, C.
    Carpo, M.
    Cocito, D.
    Vigo, T.
    Beronio, A.
    Zara, G.
    Zambello, R.
    Sormani, M. P.
    Mancardi, G. L.
    Nobile-Orazio, E.
    Schenone, A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2007, 12 : 9 - 9